DaVita Boosts 2026 EPS Forecast on Strong Q1 Revenue and Earnings Beat
summarizeSummary
DaVita reported robust first-quarter results, significantly beating analyst expectations for both revenue and adjusted EPS, and subsequently raised its full-year 2026 adjusted EPS and operating income guidance. Q1 adjusted EPS of $2.87 notably surpassed the $2.32 consensus, while revenue reached $3.42 billion against $3.36 billion expected. The company now projects 2026 adjusted diluted EPS of $14.10-$15.20, an increase from the prior $13.60-$15.00 range. This positive revision provides a strong contrast to the declining net income and EPS reported in the 2025 10-K, signaling an improved financial trajectory for the current year. The material beat and raised outlook are significant positive catalysts, indicating strong operational performance driven by increased reimbursement rates, making this highly actionable for traders, especially with the stock trading near its 52-week high. Investors will monitor the company's ability to sustain these improved trends and manage rising costs in future quarters.
At the time of this announcement, DVA was trading at $159.61 on NYSE in the Life Sciences sector, with a market capitalization of approximately $10.4B. The 52-week trading range was $101.00 to $159.42. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.